RAIsonance Launches Inexpensive, Cough-Based TB Solution in Seven Countries

Denver Tech Center, Colorado, 02/07/2025. RAIsonance, Inc. today announced the launch of its AI-powered Tuberculosis clinical decision support software, called AudibleHealth DxPro, in seven countries. This innovative, fully integrated solution uses cough sounds to detect the unique signature of a TB infection in the sound of a person’s cough. The seven launch markets include Guinea, Indonesia, Kenya, South Africa, Rwanda, the United Kingdom, and Zimbabwe.

“Our proprietary technology has been in development and rigorous testing for nearly five years and has performed beautifully in all five of our clinical studies. We are ecstatic to have reached this latest milestone toward our goal of bringing this novel, high-impact technology to high burden TB countries all over the world. We are eager to contribute to the global TB community’s mission of true TB elimination,” said Kitty Kolding, Founder and CEO at RAIsonance. 

“Our unique area of expertise is using proprietary, advanced, artificial intelligence and machine learning to analyze and interpret the incredibly rich set of data available from cough sounds. To use the solution, an individual coughs into a customized web app for 10 seconds. That recording is then pushed to the company’s cloud-based production environment in Microsoft Azure, with results returned to the clinician or community health worker in approximately 30 seconds, delivering a fast, simple, effective assessment. We’ve also created a very scalable infrastructure enabling us to process over 20,000 screenings per second, so that we can accommodate virtually any volume spikes we encounter,” explained Mark Fogarty, Chief Technology Officer at RAIsonance.

“Cough sounds – not to be confused with vocal biomarkers – carry enormous amounts of data that RAIsonance has been studying for years. For each cough collected, we analyze more than 5000 distinct data points. And because every respiratory illness or condition creates different impacts in the respiratory system such as inflammation, airway constriction, changes in mucus quantity and characteristics, etc., our data scientists have discovered an efficient, reliable way to train our models to detect these harmonic patterns in the data that correlate to specific respiratory diseases. That’s how we’re able to not just detect a specific disease but also differentiate between conditions like TB and COVID and Flu,” said Karl Kelley, Chief Medical Officer at RAIsonance. 

The company’s AudibleHealth Dx platform is designed to house more than 20 different screening solutions. At present the company offers solutions for identifying Tuberculosis, COVID-19, and, for the insurance industry, whether or not a person smokes cigarettes. Solutions for Influenza and RSV are in clinical trials, and there are another 15 additional solutions on the product roadmap including Pertussis, Pneumonia, Emphysema, Asthma, Lung Cancer, Congestive Heart Failure, and many more. Practitioners can choose to have their patient screened for one or many different conditions to provide them with as much data as possible as they assess their patients.

The AudibleHealth DxPro solution for Tuberculosis is designed to give providers and practitioners an entirely new way to assess their patients suspected of a TB infection. The goal of the screening solution is to support active case finding and create powerful new efficiencies in the TB care cascade. The solution was designed to meet or exceed all the latest TPP (Target Product Profile) criteria from the World Health Organization for utility and performance.

“Our solution is designed to rapidly, non-invasively, and inexpensively identify likely positive cases - at scale. Once identified by our solution, these individuals should undergo the standard confirmatory testing and physician evaluation needed to accurately identify an active TB case, including PCR, imaging, microscopy and sputum culture diagnostic modalities. Our role is to filter large numbers of possible TB sufferers to ensure that these expensive confirmatory tests are conducted only on those most likely to have TB. In this way, we can help high burden TB countries, global health organizations, NGOs and charitable organizations focused on TB to use their limited TB testing resources and personnel much more efficiently and cost-effectively. This way, we can help them to avoid spending heavily on the vast majority of cases that are actually negative,” said Kolding. 

“Our solution is ideal for low and middle-income countries where TB is the most prevalent. Individuals only need a smart phone and a very basic internet connection to use our technology. And because we designed this as a web app, users don’t need to interact with an app store or download and maintain a mobile app to use the solution. We simply send them a link via SMS or WhatsApp, which launches a mobile browser to allow them to quickly record their cough sounds using our specialized technology,” said Kris Hopkins, Chief Product Officer at RAIsonance. 

“To bring our solution to market, we’re activating partnerships with local companies in telehealth, pharmacies, digital health, and of course clinics and hospitals. It’s exciting to work with these talented, knowledgeable partners to introduce this solution to markets they understand,” said Kraig Monteferrante, SVP of Global Partnerships for RAIsonance.  

RAIsonance is a family of companies headquartered in the Denver Tech Center, dedicated to Artificial Intelligence/Machine Learning (AI/ML)-based healthcare solutions. RAIsonance companies operate a suite of wellness products including MyAdvocate for individuals with chronic respiratory conditions, and FCV Sentinel for groups, teams, and enterprise applications. It also operates a disease screening platform called AudibleHealth Dx designed to screen for specific respiratory conditions including  COVID-19, Influenza, Tuberculosis, and RSV. To learn more about RAIsonance Inc., please visit RAIsonance.ai.

Anne E. Humpich 
Email: Press@RAIsonance.ai